Zymeworks Inc

Zymeworks Inc. is a biopharmaceutical company. It engages in the discovery, development, and commercialization of multifunctional biotherapeutics, initially focused on the treatment of cancer. The company is headquartered in Middletown, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zymeworks reports turnaround year with strong financials and R&D progress

Zymeworks delivered a strong financial performance in 2022, driven by revenue growth and cost management efforts.
The company faces challenges in managing increased expenses and addressing analyst inquiries on data disclosure and product development.
Despite challenges, Zymeworks remains well-positioned with ample cash resources and a robust R&D pipeline for future growth.
Opportunities lie in expanding partnerships, leveraging positive trial data, and showcasing innovation at upcoming industry events.

Zymeworks Inc reports revenue growth and strategic R&D advancements

Zymeworks Inc's Q1 2023 performance reflects positive financial trends and advancements in their R&D programs and partnerships.
While challenges exist with the Jazz agreement and future clinical trials, the company is strategically positioned for growth.
Opportunities in global collaborations, capital allocation, and innovative therapies position Zymeworks for future success and market expansion.

Zymeworks reports improved financials, advances global clinical expertise

Zymeworks Inc's Q2 2023 performance reflects a mixed financial picture with revenue growth but increased expenses, while maintaining a healthy cash position.
The company's strengths lie in advancing its product pipeline, leveraging partnerships for efficient development, and establishing global clinical expertise.
Challenges include timeline uncertainties, competitive landscape considerations, and operational complexities in clinical trial development.
Opportunities abound in therapeutic advancements, strategic partnerships, and long-term financial sustainability through disciplined management.

Zymeworks Inc reports improved financials and optimistic drug outlook

Zymeworks Inc's Q3 2023 performance reflects improved financials driven by revenue growth from collaborations, cost management strategies, and operational streamlining.
The company's strengths lie in new IND candidates, positive outlook on key drug opportunities, and confidence in study designs and treatment efficacy.
Challenges include managing expense trajectories, balancing cost structures, and optimizing cash resources for sustained operations and growth.
Opportunities abound in continued collaboration benefits, pipeline expansion in targeted cancer therapies, and advancements in preclinical assets for future clinical studies.

Zymeworks accelerates pipeline development with positive clinical results and partnerships

Zymeworks demonstrated positive performance in clinical trials and financial management in Q4 2023.
Strengths lie in pipeline progress, resource independence, and potential milestone payments.
Challenges include financial losses, competition, and the need for strategic partnerships.
Opportunities exist in partnerships, milestone payments, and upcoming data readouts for market impact.

Zymeworks Inc reports Q1 loss, focuses on T cell enhancement

Zymeworks Inc is strategically positioned to advance its clinical development programs and strengthen its presence in key locations for upcoming trials. The company is committed to executing its plan efficiently, focusing on enhancing T cell responses and exploring opportunities for sustainable growth.

Zymeworks reports Q2 losses, advances oncology pipeline with FDA clearances

Zymeworks' Q2 2024 performance reflects a mix of financial challenges and strategic advancements in drug development and regulatory milestones.
The company's strengths lie in its pipeline progress, strategic decision-making, and focus on growth through key appointments and partnerships.
While facing challenges in financial metrics and product timelines, Zymeworks has opportunities to leverage its resources for future growth and innovation.

Zymeworks reports revenue decline but showcases strength in innovation and financial strategy

Zymeworks reported a decline in revenue and a net loss for Q3 2024, reflecting ongoing financial challenges.
Despite this, the company showcased strengths in preclinical data, share repurchase program, and commitment to innovation.
Navigating market conditions and managing expenses will be crucial, but Zymeworks has opportunities in new therapeutic areas and strategic initiatives.
Investors should monitor the company's progress, especially with the upcoming R&D Day and potential advancements in its pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zymeworks Inc. (ZYME) Soars 5.3%: Is Further Upside Left in the Stock?

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the closing of its previously announced underwritten public offering of 11,035,000 common shares, including the exercise in full of the underwriters' option to purchase 1,875,000 additional shares, and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,340,000 common shares

Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Zymeworks Inc. (ZYME) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 48.4% in 4 Weeks, Here's Why Zymeworks Inc. (ZYME) Looks Ripe for a Turnaround

Asbury Automotive Group

JAKKS Pacific

Medifast

Polaris

Want to try a different approach? Tap five stocks with increasing P/E ratios such as MEDIFAST (MED), JAKKS Pacific (JAKK), Asbury Automotive Group (ABG), Zymeworks (ZYME) and Polaris (PII).

Bank on Rising P/E Investing With These 5 Top-Ranked Stocks

Zymeworks is looking to raise $100 million in a public offering, barely a week since new CEO Kenneth Galbraith took the reins of the biotech company, which has operations in Seattle and Vancouver, B.

Zymeworks aims to raise $100M in public offering amid leadership shakeup

The shares are offered at $8.00 per common share and the pre-funded warrants at $7.9999 per pre-funded warrant.

Zymeworks Raises $100M Via Equity Issued At 14% Discount

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the pricing of its underwritten public offering of 9,160,000 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,340,000 common shares. The common shares are being offered at a public offering price of $8.00 per common share and the pre-funded warrants are

Zymeworks Announces Pricing of $100.0 Million Public Offering

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may

Zymeworks Announces Proposed Public Offering

Kenneth Galbraith is shaking up Zymeworks within a week of becoming CEO of the Seattle and Vancouver, B.

New CEO at Zymeworks shifts leadership, plans to lay off 25% of staff

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today provided a corporate update on its key strategic priorities for 2022 and 2023 in addition to confirming its upcoming clinical development milestones for zanidatamab and ZW49. “Upon assuming my new role effective January 15th, we have moved quickly to review and confirm key strategic priorities for the near term and to e

Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE Rule”), an equity inducement award to Mr. Kenneth Galbraith, Zymeworks' new Chair, President and Chief Executive Officer. In accordance with the NYSE Rule, Zymeworks approved the grant of the following equity award to Mr.

Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Neil Klompas, Zymeworks' Chief Operating Officer and Chief Financial Officer, will present at the upcoming 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 at 9:45 a.m. ET. The presentation will be webcast live and available for replay on Zymeworks' website at http://ir.zymeworks.com/even

Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani

Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its collaborator, BeiGene, Ltd., has dosed the first patient in South Korea in the HERIZON‑GEA‑01 trial. As a result of this development milestone, Zymeworks will receive a US$8 million payment under its zanidatamab collaboration agreement with BeiGene. Zymeworks and BeiGene continue to work to expedite the opening

Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity

Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Janssen Biotech, Inc. (“Janssen”) dosed the first patient with JNJ-78306358, a bispecific antibody developed using Zymeworks' Azymetric™ and EFECT™ therapeutic platforms. This is the second Janssen bispecific program utilizing Zymeworks' proprietary technology platforms to enter the clinic this year, following the

Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)

Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Names Neil Josephson, M.D., Chief Medical Officer

Zymeworks Names Neil Josephson, M.D., Chief Medical Officer

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2 Positive Gastroesophageal Adenocarcinoma (GEA)

Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming investor conferences. Stifel 2021 Virtual Healthcare Conference, November 16th – 17th. Zymeworks is participating in a fireside chat on November 17th at 1:20 p.m. ET. Jefferies London Healthcare Conference, November 18th – 19th. Zymeworks' pre-recorded presentation will

Zymeworks to Present at Upcoming Investor Conferences

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -5.93% and -50.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Reports Q3 Loss, Misses Revenue Estimates

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Zymeworks Inc. (ZYME) Report Negative Q3 Earnings? What You Should Know

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will host a conference call and webcast to provide details related to the launch of its Phase 3 first-line gastroesophageal adenocarcinoma (GEA) pivotal study, HERIZON-GEA-01, and to discuss the commercial potential of zanidatamab in gastrointestinal cancers. HERIZON-GEA-01 is a randomized, global Phase 3

Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers

Zymeworks (ZYME) has been struggling lately, but the selling pressure may be coming to an end soon.

Zymeworks (ZYME) Sees Hammer Chart Pattern: Time to Buy?

Zymeworks Inc. (ZYME) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

News for Zymeworks Inc Stock (ZYME)